The share of flu tests coming back positive rose from 3.9% to 5% in the week ending Oct. 10, the CDC’s first FluView report of the 2026-27 season shows. ED visits and outpatient visits for flu also climbed.
Seasonal flu activity remains low, but test positivity, outpatient visits for flu-like illness, ED visits with a flu diagnosis and lab-confirmed hospitalizations have all been rising since late August or early September. Activity is highest on the West Coast, and the CDC said early-season levels are higher than typical for this time of year but within expected seasonal variation. Influenza A(H1N1) accounted for 96.4% of the influenza A viruses that public health labs subtyped during the week.
Here are six things to know:
- Clinical labs reported 2,270 positive specimens, or 5% of those tested, up from 3.9% the week prior. Positivity rose nationally and in HHS Regions 4, 6, 7, 8 and 9 and held stable in Regions 1, 2, 3, 5 and 10.
- Zero point eight percent of ED visits carried a flu diagnosis, an increase from the previous week. Visits rose among children 4 and younger and ages 5 to 17 and held steady among adults. Last week’s report put the share at 0.6%.
- Flu-like illness accounted for 2.1% of outpatient visits, an increase from Week 39 but below the national baseline of 2.9%. One jurisdiction reached moderate activity and five were at low activity, up from none and two, respectively, the week before.
- Hospitals reported 4,024 lab-confirmed flu admissions. The admission rate of 1.2 per 100,000 people was stable compared with Week 39. Admission rates rose among children 4 and younger and adults 65 and older. Adults 65 and older had the highest rate at 3.8 per 100,000, followed by children 4 and younger at 1.3.
- Eight H1N1 viruses carried mutations that reduced inhibition by oseltamivir. That is 3.1% of the 259 H1 viruses tested since May 24. None showed reduced susceptibility to baloxavir, peramivir or zanamivir.
- Of 74 H1N1 viruses antigenically characterized, 94.6% were well recognized by antisera to the vaccine reference virus. All H3N2 and B/Victoria viruses tested were also well recognized. No pediatric flu deaths have been reported for the 2026-27 season.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
